Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook

-- Cash and Cash Investments at December 31, 2025 of €116.5 Million and Gross Proceeds of $208 Million from Initial Public Offering (IPO) Expected to Extend Cash Runway into First Half of 2029 --

-- Positive Interactions with U.S. Food and Drug Administration (FDA) on Design of Phase 2b Study with Ontunisertib in Fibrostenosing Crohn’s Disease (FSCD) --

-- On Track to Initiate Phase 2b Study in FSCD with Ontunisertib and Phase 2 Study in Idiopathic Pulmonary Fibrosis (IPF) with AGMB-447 in Second Half of 2026 --

-- Topline Data from Open-Label Long-term Extension Study (OLE) Part of STENOVA Study with Ontunisertib in FSCD and from Phase 1b IPF Study Cohort with AGMB-447 Expected in Second Half of 2026 --

Antwerp, Belgium, April 23, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today reported financial results for the full year period ended December 31, 2025, and confirmed its outlook for 2026.

“2025 was a pivotal year for Agomab, with significant progress across our clinical programs and the positive topline results of the STENOVA Phase 2a study with ontunisertib in FSCD. Our momentum has continued into 2026 with positive Phase 1 results for AGMB-447 in healthy participants and the successful completion of our IPO,” said Tim Knotnerus, Chief Executive Officer of Agomab. “In the second half of this year, we expect the full read-out of the OLE study with ontunisertib in FSCD as well as the topline IPF cohort data of the Phase 1b study with AGMB-447. Based on the positive regulatory interactions on trial design, we are on track to start both the Phase 2b study with ontunisertib in FSCD and Phase 2 study with AGMB-447 in IPF later this year.”

Pierre Kemula, Chief Financial Officer of Agomab, added, “Thanks to the $208 million in gross proceeds raised from our IPO in February 2026, we are well-capitalized and we expect our cash reserves to last into the first half of 2029. With major milestones approaching later this year, we remain laser-focused on delivering on our corporate and clinical strategy.”

Recent Program Highlights and 2026 Anticipated Milestones 

• Ontunisertib (AGMB-129), a gut-restricted small molecule inhibitor of ALK5 for the treatment of FSCD 

• • We continue to have positive interactions with the FDA to align on the study design of the Phase 2b study with ontunisertib in FSCD and are on track to initiate the study in the second half of 2026.
  • We are progressing the OLE part of the STENOVA study (Part B) with ontunisertib in FSCD patients, with topline results expected in the second half of 2026. The 48-week data may provide important insights into extended treatment with ontunisertib in FSCD patients.
  • As of February 2026, the Data Safety and Monitoring Board has not raised any safety issue and has recommended for the OLE study to continue as per the protocol with 200mg BID ontunisertib for up to 60 weeks.
  • The results of the 12-week placebo-controlled double-blind part of the STENOVA Phase 2a study with ontunisertib in FSCD (Part A) were presented as a late-breaker at the 21st Congress of ECCO (ECCO’26) in Stockholm, Sweden in February 2026. The late-breaking presentation was also featured by Nature Reviews Gastroenterology & Hepatology as one of the highlights of ECCO’26.

• AGMB-447, an inhaled small molecule inhibitor of ALK5 in development for the treatment of IPF

• • We continue to enroll participants in the IPF cohort of the Phase 1b study with AGMB-447. In this cohort, up to 12 participants with IPF will receive multiple doses of AGMB-447 or placebo over 14 days. We have dosed the first participants, and expect to report topline results in the second half of 2026.
  • We received positive scientific advice from the UK Medicines and Healthcare products Regulatory Agency (MHRA), supporting our planned Phase 2 trial in IPF patients. We are on track to initiate a Phase 2 proof-of-concept study with AGMB-447 in IPF in the second half of 2026.
  • We were granted a patent covering the composition of matter of AGMB-447 by the United States Patent and Trademark Office (USPTO), solidifying the foundational IP for AGMB-447 in the U.S.

Full Year 2025 Financial Results (consolidated)

• Cash Position: Cash, cash equivalents and short-term cash investments totaled €116.5 million as of December 31, 2025. Subsequently, in February 2026, we completed our IPO, in which we raised gross proceeds of approximately $208 million, including the proceeds from the underwriters’ partial exercise of their overallotment option, before deducting underwriting discounts and commissions and other offering expenses. We expect that our existing cash and cash investments, including the net proceeds from our IPO, will enable us to fund our operating expenses and capital expenditure requirements into the first half of 2029.
• R&D Expenses: Research and development (R&D) expenses were €48.9 million for the year ended December 31, 2025, as compared with €39.3 million for the year ended December 31, 2024. The increase in R&D expenses of €9.6 million for the year was primarily due to increased clinical trial expenses, which are outsourced activities, specifically for the two lead programs ontunisertib and AGMB-447.
• G&A Expenses: General and administrative (G&A) expenses were €12.8 million for the year ended December 31, 2025, as compared with €10.1 million for the year ended December 31, 2024. The increase of €2.7 million for the year mainly relates to increased employee benefits, reflecting organizational scaling to support company growth, including stock-based compensation.
• Net Loss: Net loss was €62.5 million for the full year ended December 31, 2025, compared to €46.3 million for the full year ended December 31, 2024.

Corporate

• The company has filed its Annual Report on Form 20-F with the U.S. Securities and Exchange Commission (SEC). The Annual Report is available on the Agomab website at https://agomab.com/ and on the SEC’s website at www.sec.gov.
• The company will hold its Annual General Meeting (AGM) at 4:00pm CEST on May 26, 2026. The convening notice for the AGM as well as all documents relevant for the meeting are available via the Agomab website at https://ir.agomab.com/governance/shareholder-meetings. 

  

Financial performance

Consolidated statement of profit and loss

             For the year ended December 31(in thousands of €), except per share data        2025    2024    2023Research and development expenses   (48,877)  (39,310)  (26,311)General and administrative expenses   (12,791)  (10,133)  (6,097)Total operating expenses   (61,668)  (49,443)  (32,408)        Other operating income   2,393  1,422  1,218Operating loss   (59,275)  (48,021)  (31,190)        Changes in fair value of financial liabilities    (4,857)  848  18,964Financial expenses    (133)  (357)  (86)Financial income   1,718  1,267  303Loss before taxes   (62,547)  (46,263)  (12,009)        Income tax (expense)/income   —  (4)  619Loss for the year    (62,547)  (46,267)  (11,390)        —Weighted average number of common shares outstanding    541,126  541,126  541,126Basic and diluted loss per share (in €)   (143.22)  (107.09)  (35.63)

 

 

   For the year ended December 31(in thousands of €)        2025    2024    2023Loss for the year   (62,547)  (46,267)  (11,390)Items that may be reclassified to profit or loss       Foreign currency translation differences   21  (10)  —Items that will not be reclassified to profit or loss       Remeasurement of post-employment benefit obligations   (8)  (73)  —Other comprehensive income or loss for the year, net of tax   13  (83)  —Total comprehensive income or loss for the year   (62,534)  (46,350)  (11,390)   

Consolidated statement of financial position

   For the year ended per     December 31 (In thousands of €)        2025    2024 Assets       Non-current assets       Intangible assets   20,110  20,110 Goodwill    8,612  8,612 Property, plant and equipment   503  619 Right-of-use assets    1,083  1,373 Other financial assets    11  12 Other non-current assets    2,150  1,787 Total non-current assets   32,469  32,513        Current assets       Other current assets    4,723  2,386 Current financial investments   30,096  — Cash and cash equivalents   86,418  171,459 Total current assets   121,237  173,845 Total assets   153,706  206,358        Equity       Share capital    223,072  223,072 Share premium reserve    76,634  76,634 Retained earnings   (181,714)  (119,181) Share-based payment reserves   13,877  8,522 Other reserves    (967)  (966) Equity attributable to the owners of the parent   130,902  188,081 Total equity   130,902  188,081        Liabilities       Non-current liabilities       Non-current lease liabilities    1,005  1,272 Non-current contingent consideration   3,210  7,879 Total non-current liabilities   4,215  9,151        Current liabilities       Current lease liabilities    249  273 Anti-dilutive warrants    —  — Current contingent consideration   6,526  — Trade and other payables   10,266  8,052 Deferred income and accrued charges   1,548  801 Total current liabilities   18,589  9,126 Total liabilities    22,804  18,277        Total equity and liabilities   153,706  206,358                            

Consolidated statement of cash flows

  For the years ended per December 31(In thousands of €)    2025    2024    2023Net loss for the year  (62,547)  (46,267)  (11,390)Adjustments for non-cash items:               Current income tax expense (income)  —  4  3Deferred income tax expense (income)   —  —  (622)Fair value (gain) loss on financial assets  (96)  —  —Fair value (gain) loss on financial liabilities  4,857  (848)  (18,964)Depreciation & amortization   219  311  99Share-based payment expenses  5,355  1,071  2,159Net foreign exchange losses (gains)   57  231  —Interest expense  69  77  86Interest income   (1,614)  (1,218)  (303)Operating cash flows before movements in working capital   (53,700)  (46,640)  (28,932)       movements in working capital:               Decrease/(increase) in other current assets   (2,337)  (315)  1,343Decrease/(increase) in other non-current assets   (363)  (342)  (331)Increase/(decrease) in trade and other payables  2,359  (230)  3,686Increase/(decrease) in deferred income  747  (395)  (580)       Income taxes paid  —  (4)  (3)Interest paid   (69)  (10)  (20)Interest received   1,622  1,106  245Net cash flow from /(used in) operating activities   (51,741)  (46,828)  (24,592)       Purchases of property, plant and equipment   (4)  (675)  —Purchase of financial investments  (30,000)  —  40,000Payment of contingent consideration from previous acquisition  (3,000)  —  —Net cash flow from /(used in) investing activities   (33,004)  (675)  40,000       Repayment of lease liabilities   (338)  (163)  (100)Proceeds from capital increase  —  97,055  79,871Share issue costs  —  (129)  (453)Other financial expense, net   —  —  6Net cash flow from /(used in) financing activities  (338)  96,762  79,324       Net increase/(decrease) in cash and cash equivalents  (85,083)  49,260  94,732       Cash and cash equivalents at beginning of year   171,459  122,402  27,670Effect of foreign exchange rate changes  45  (204)  —Cash and cash equivalents at end of year   86,418  171,459  122,402   

Ontunisertib and AGMB-447 are investigational drugs and not approved by any regulatory authority. Their efficacy and safety have not been established.  


About Agomab
Agomab is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for fibro-inflammatory diseases with high unmet medical need. Agomab’s product candidates are designed to target established potent pathways and utilize organ-restricted approaches, with the aim of increasing efficacy while minimizing safety liabilities. Fostering a culture of excellence, Agomab’s mission is to pioneer therapeutics that aim to resolve fibro-inflammation and restore organ function to enable people with these disorders to live fuller and healthier lives.

Cautionary Note Regarding Forward-Looking Statements
This press release includes certain disclosures that contain “forward-looking statements,” including, without limitation, statements regarding our expected cash runway, including that we anticipate our cash and cash investments and IPO proceeds will extend our runway into the first half of 2029, our focus on the discovery and development of our pipeline of novel product candidates for fibro-inflammatory disorders, the design of planned Phase 2 clinical trials with ontunisertib for FSCD and AGMB-447 for IPF, our expectation to initiate our Phase 2b Study of ontunisertib in FSCD and our Phase 2 study of AGMB-447 in IPF in the second half of 2026, as well as statements regarding future data readouts, including our expectation to release topline data from the OLE part of the STENOVA study and of the Phase 1b IPF Study Cohort with AGMB-447 in the second half of 2026. Forward-looking statements are based on Agomab’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to the results of our clinical trials; expectations regarding the inherent uncertainties associated with the development of novel drug therapies; preclinical and clinical trial and product development activities and regulatory approval requirements for product candidates; the impact of governmental laws and regulations on our business; disruptions caused by our reliance on third party suppliers and service providers; the risk that our expectations and management’s guidance regarding our cash position and other financial estimates may be incorrect; and risks related to geopolitical conflicts and macro-economic events. These and other risks and uncertainties are described more fully in our filings and reports with the SEC, including in our most recent annual report on Form 20‐F filed with the SEC and our subsequent filings and reports filed with the SEC. Forward-looking statements contained in this announcement are made as of this date, and Agomab undertakes no duty to update such information except as required under applicable law. Readers should not rely upon the information in this announcement as current or accurate after its publication date.

Contacts
Investors
Sofie Van Gijsel
VP of Investor Relations
E-Mail: [email protected]
Phone: +1 781 296 1143

Media
Gretchen Schweitzer
Trophic Communications
E-Mail: [email protected] 
Phone: +49 172 861 8540